Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma
Urey, Carlos LU ; Hilmersson, Katarzyma Said LU ; Andersson, Bodil LU
; Ansari, Daniel
LU
and Andersson, Roland
LU
(2017)
In Anticancer research
37(11).
p.6031-6039
- Abstract
CONCLUSION: Successful development and characterization of a MUC4-targeted immunoliposome shows promising results for a targeted treatment and improved retention of gemcitabine for treatment of PDAC.
RESULTS: Development of a MUC4-targeted immunoliposome was confirmed and characterized by immunoblots and size characterization. The MUC4-targeted immunoliposome showed a significantly higher targeting affinity compared to the non-targeted liposomes and also showed an improved antiproliferative effect compared to free and non-targeted liposomal drug.
BACKGROUND/AIM: Pancreatic Ductal adeno-carcinoma (PDAC) is a devastating disease. Gemcitabine is the standard chemotherapeutic agent against PDAC but has only limited... (More)
CONCLUSION: Successful development and characterization of a MUC4-targeted immunoliposome shows promising results for a targeted treatment and improved retention of gemcitabine for treatment of PDAC.
RESULTS: Development of a MUC4-targeted immunoliposome was confirmed and characterized by immunoblots and size characterization. The MUC4-targeted immunoliposome showed a significantly higher targeting affinity compared to the non-targeted liposomes and also showed an improved antiproliferative effect compared to free and non-targeted liposomal drug.
BACKGROUND/AIM: Pancreatic Ductal adeno-carcinoma (PDAC) is a devastating disease. Gemcitabine is the standard chemotherapeutic agent against PDAC but has only limited effectiveness. The aim of the study was to develop and study the targeting affinity and in vitro antiproliferative effect of a MUC4-targeted gemcitabine-loaded immuno-liposome for treatment of PDAC.
MATERIALS AND METHODS: Gemcitabine-loaded immunoliposomes were developed by grafting anti-MUC4 antibodies to the liposomal surface. Targeting affinity was compared in vitro between immunoliposomes and non-targeted liposomes and anti-proliferative effect was compared in vitro between free drug, non-targeted liposomal gemcitabine and MUC4-targeted immunoliposomal gemcitabine on a MUC4-positive pancreatic cancer cell line, Capan-1.
(Less)
- author
- Urey, Carlos
LU
; Hilmersson, Katarzyma Said
LU
; Andersson, Bodil
LU
; Ansari, Daniel
LU
and Andersson, Roland
LU
- organization
- publishing date
- 2017-11-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Capan-1, drug delivery, Gemcitabine, Immunoliposomes, MUC4, pancreatic ductal adenocarcinoma
- in
- Anticancer research
- volume
- 37
- issue
- 11
- pages
- 9 pages
- publisher
- International Institute of Cancer Research
- external identifiers
-
- pmid:29061782
- scopus:85032507780
- ISSN
- 1791-7530
- language
- English
- LU publication?
- yes
- id
- b9df247e-5c5e-43ad-904b-1e3302c4679b
- date added to LUP
- 2017-11-12 16:13:09
- date last changed
- 2024-03-01 01:57:20
@article{b9df247e-5c5e-43ad-904b-1e3302c4679b,
abstract = {{<p>CONCLUSION: Successful development and characterization of a MUC4-targeted immunoliposome shows promising results for a targeted treatment and improved retention of gemcitabine for treatment of PDAC.</p><p>RESULTS: Development of a MUC4-targeted immunoliposome was confirmed and characterized by immunoblots and size characterization. The MUC4-targeted immunoliposome showed a significantly higher targeting affinity compared to the non-targeted liposomes and also showed an improved antiproliferative effect compared to free and non-targeted liposomal drug.</p><p>BACKGROUND/AIM: Pancreatic Ductal adeno-carcinoma (PDAC) is a devastating disease. Gemcitabine is the standard chemotherapeutic agent against PDAC but has only limited effectiveness. The aim of the study was to develop and study the targeting affinity and in vitro antiproliferative effect of a MUC4-targeted gemcitabine-loaded immuno-liposome for treatment of PDAC.</p><p>MATERIALS AND METHODS: Gemcitabine-loaded immunoliposomes were developed by grafting anti-MUC4 antibodies to the liposomal surface. Targeting affinity was compared in vitro between immunoliposomes and non-targeted liposomes and anti-proliferative effect was compared in vitro between free drug, non-targeted liposomal gemcitabine and MUC4-targeted immunoliposomal gemcitabine on a MUC4-positive pancreatic cancer cell line, Capan-1.</p>}},
author = {{Urey, Carlos and Hilmersson, Katarzyma Said and Andersson, Bodil and Ansari, Daniel and Andersson, Roland}},
issn = {{1791-7530}},
keywords = {{Capan-1; drug delivery; Gemcitabine; Immunoliposomes; MUC4; pancreatic ductal adenocarcinoma}},
language = {{eng}},
month = {{11}},
number = {{11}},
pages = {{6031--6039}},
publisher = {{International Institute of Cancer Research}},
series = {{Anticancer research}},
title = {{Development and In Vitro Characterization of a Gemcitabine-loaded MUC4-targeted Immunoliposome Against Pancreatic Ductal Adenocarcinoma}},
volume = {{37}},
year = {{2017}},
}